Pharma Deals Review, Vol 2007, No 90 (2007)

Font Size:  Small  Medium  Large

Dynavax Licenses HBV Vaccine to Merck & Co.

Business Review Editor

Abstract


Dynavax Technologies and Merck & Co. entered into license agreement for Dynavax’s Heplisav™ an investigational vaccine for hepatitis B virus. The deal would worth up to US$136.5 M to Dynavax.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.